KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $93.5 million.

  • Royalty Pharma's Free Cash Flow fell 6202.34% to $93.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $792.1 million, marking a year-over-year increase of 20085.04%. This contributed to the annual value of $792.1 million for FY2025, which is 20085.04% up from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Free Cash Flow is $93.5 million, which was down 6202.34% from -$259.3 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Free Cash Flow registered a high of $595.0 million during Q1 2025, and its lowest value of -$866.3 million during Q3 2021.
  • In the last 5 years, Royalty Pharma's Free Cash Flow had a median value of $282.2 million in 2021 and averaged $107.8 million.
  • In the last 5 years, Royalty Pharma's Free Cash Flow soared by 246727.37% in 2021 and then plummeted by 50114.8% in 2024.
  • Over the past 5 years, Royalty Pharma's Free Cash Flow (Quarter) stood at $318.2 million in 2021, then increased by 0.46% to $319.7 million in 2022, then tumbled by 171.82% to -$229.6 million in 2023, then surged by 207.18% to $246.1 million in 2024, then tumbled by 62.02% to $93.5 million in 2025.
  • Its Free Cash Flow stands at $93.5 million for Q4 2025, versus -$259.3 million for Q3 2025 and $362.9 million for Q2 2025.